Pharmaceutical and medical device manufacturers face relentless and costly waves of product liability claims across U.S. federal and state courts, spanning individual suits, consolidated multidistrict litigation and coordinated proceedings, multi-plaintiff actions, and class actions. As this complex area of litigation continues to expand-often into more treacherous and plaintiff-friendly venues-the stakes for getting strategy right, early and often, have never been higher.
The third edition of
Drug and Device Product Liability Litigation Strategy equips litigators with clear, practical guidance from pre-litigation investigations through trial. Reflecting significant developments since the prior edition, it distills the current and evolving legal landscape impacting drug and device lawyers, and offers actionable analysis on the issues that are most likely to influence outcomes: pre-litigation investigation and risk assessment, document preservation and fact discovery, coordination in MDLs and state proceedings, class action challenges, developments in preemption and personal jurisdiction case law, admissibility of expert testimony, dispositive and pre-trial motion practice, jury selection, and trial strategy.
This edition highlights strategic inflection points and delivers practice-oriented insights to streamline case management and sharpen advocacy. With its emphasis on strategy and results, it is an indispensable resource for lawyers navigating high-profile drug and device litigation in a continually shifting environment.
